ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). (Q38061883)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

5

object named as

J Walewski

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

M Ghielmini

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

U Vitolo

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

E Kimby

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S Montoto

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

M Pfreundschuh

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

P Hoskin

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

C McNamara

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

F Caligaris-Cappio

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S Stilgenbauer

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

R Marcus

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

P Dreger

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

E Montserrat

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

M Dreyling

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

M Federico

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

21 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

561-576

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Double-hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

The Day One Talk

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Chronic lymphocytic leukemia and autoimmunity: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

TP53 mutation and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS517

21 January 2018

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From pathogenesis to treatment of chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease-specific complications of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Understanding and managing ultra high-risk chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Reg

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Basic assessment of the older cancer patient

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDS517

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23175624%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38061883&oldid=1903463246"